UK government agrees fourth Covid vaccine deal

Latest

UK government agrees fourth Covid vaccine deal

In Latest

The UK Government has signed a fourth coronavirus vaccine deal, this time with GSK and Sanofi Pasteur.

The two companies will supply the UK with 60 million doses of their protein adjuvant Covid-19 vaccine, which is based on existing DNA-based technology used to produce Sanofi’s flu vaccine. Human clinical studies of the vaccine will begin in September followed by a phase 3 study in December 2020.

The government has now secured early access to four different types of immunisation and a total of 250 million doses. Deals for other different vaccine classes have been agreed with:

  • BioNTech/Pfizer – the UK has secured 30 million doses of its mRNA vaccine
  • Valneva – in principle agreement for 60 million doses. If the vaccine is proven to be safe, effective and suitable, the UK has secured an option to acquire a further 40 million doses of this inactivated whole virus vaccine
  • Oxford/AstraZeneca – in principle agreement for one million doses of its adenoviral ChAdOx1 nCoV-19 vaccine.

In addition the UK has secured rights to AstraZeneca’s antibody treatment to neutralise the virus which can be used both as a short term prophylactic for those people who cannot receive vaccines, such as cancer and immunosuppressed patients, and front line workers exposed to the virus, as well as a treatment for infected patients.

Interim advice from the Joint Committee on Vaccination and Immunisation (JCVI) has advised priority vaccination for frontline health and social care workers, and those at increased risk of serious disease and death from Covid-19 infection stratified according to age and risk factors.

Promising early results from Oxford vaccine

Early stage human trials of the Covid-19 vaccine being developed at Oxford University’s Jenner Institute and Oxford Vaccine Group have found it produces strong immune response and shows no early safety concerns, according to results published in The Lancet.

The vaccine is similar to a vaccine the team previously developed for the closely related MERS coronavirus, which showed promise in animal and early-stage human testing.

The results of the Phase I/II trial, which started in April, indicate no early safety concerns, and both T-cell and antibody responses against the SARS-CoV-2 virus, including robust neutralising antibody responses, were demonstrated.

Between April 23, 2020 and May 21, 2020, 1077 volunteers aged 18-55 received the ChAdOx1 nCoV-19 vaccine or a placebo MenACWY vaccine. A subset of these volunteers (10 people) received two doses of the vaccine. There were no serious adverse health events related to ChAdOx1 nCoV-19.

In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked 14 days after vaccination. Anti-spike IgG responses rose by day 28, and were boosted following a second dose. Neutralising antibody responses against SARS-CoV-2 were detected in 91 to 100 per cent after a single dose depending on the assay method used.

After a booster dose, all participants had neutralising activity between 42 and 56 days after dosing. Neutralising antibody responses correlated strongly with antibody levels.

Professor Fiona Watt, executive chair of the Medical Research Council, which helped to fund the trial, said: “It is truly remarkable how fast this vaccine has progressed through early clinical trials, and it is very encouraging that it shows no safety concerns and evokes strong immune responses.

“There is a lot that we don’t yet know about immunity to the virus that causes Covid-19. However, it seems that both antibody and T cell immunity are important, and this vaccine triggers both responses. The much-anticipated next milestone will be the results of the larger trials that are happening now to find out if the vaccine will protect people from the virus.”

Record my learning outcomes

Latest

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
Latest

Extremely vulnerable patients told to shield once more

The Government has written to people who are defined on medical grounds as extremely vulnerable, outlining updated guidance on shielding.

1 Min Article

bookmark_icon_off
Latest

NHS rolls out capsule cameras to test for colon cancers

Initial group of 11,000 NHS patients in England will receive capsule cameras in 40 parts of the country.

1 Min Article

bookmark_icon_off
Latest

Research opportunity: Covid-19 outcomes for ethnic minorities

The GPhC is encouraging health professionals, including pharmacy technicians, to take part in an urgent public health study.

1 Min Article

bookmark_icon_off
Latest

DHSC secures extra supplies of flu vaccine for pharmacies

The Government hopes additional supplies will boost the largest ever flu vaccination programme in 2020-21.

1 Min Article

bookmark_icon_off
Latest

Lloyds to close more stores as online business booms

A "small number" of LloydsPharmacy stores may soon be closed due to the financial impact Covid-19 is having on the business.

1 Min Article

bookmark_icon_off
Latest

Cutting costs leads to profit boost for Lloyds parent company

LloydsPharmacy parent company McKesson saw a 16 per cent profit rise in its European division in the most recent financial quarter.

1 Min Article

Recommended Learning

Sponsored education

Supporting women in their contraceptive choices

Upgrade your contraceptive consultations by exploring the interactive pack to learn about a daily oral contraceptive pill

8 Min Module

Videos

Advising on very dry and eczema-prone skin

This video will guide you through a consultation with Michelle, a customer with very dry skin, and help you recommend suitable products to help

2 Min Module

Bayer Business Programme

Retail ready: Building confidence in retail skills - Module

How to make the most of technology and the commercial opportunites it offers

10 Min Module

bookmark_icon_off
Sponsored education

Helping customers treat & care for their scalp

Understanding the causes and symptoms of some common scalp conditions will help you to make a real difference to your customers’ lives. Complete this module to discover self-care and product advice to help ease symptoms and maintain scalp health.

10 Min Module

Sponsored education

Constipation: Making effective recommendations

Learn how to help customers with constipation and find out how even brief conversations can have a positive influence on their health.

15 Min Module

bookmark_icon_off
Videos

Advising on thrush treatment

This video looks at the distinctive benefits of different combination products and how to find the right treatment option for your customer.

7 Min Module